Does Cigna Cover ADHD Treatment in Delaware? A 2026 Guide

Last updated: July 23, 2026

If you have Cigna health insurance in Delaware and you or a family member has been diagnosed with ADHD, understanding what your plan may cover. And what steps to take before your first appointment. Can save you time, money, and frustration. This guide breaks down how Cigna may cover ADHD treatment in Delaware in 2026, including the role of its pharmacy benefit manager (PBM) Express Scripts (ESI), Cigna’s PA Policy IP0477, Delaware’s EPCS (Electronic Prescribing of Controlled Substances) requirements, and your rights under Delaware’s mental health parity law.

Coverage varies by plan, and this page provides general guidance only. Always verify your specific benefits by calling the member services number on your Cigna ID card before scheduling an appointment.

Ready to explore ADHD treatment? Klarity Health connects you with 2,000+ licensed providers across Delaware who can evaluate your symptoms, review your insurance benefits, and. If clinically appropriate. Prescribe ADHD medications through a convenient telehealth visit. See if you may qualify for ADHD treatment through Klarity →

Key Facts: Cigna ADHD Coverage in Delaware (2026)

• Insurer: Cigna Health and Life Insurance Company
• Pharmacy Benefit Manager (PBM): Express Scripts (ESI)
• PA Policy IP0477 (eff. May 15, 2026): ALL stimulant medications. Including generic methylphenidate and amphetamine salts. Require prior authorization. This applies regardless of tier.
• Delaware EPCS: Schedule II stimulant medications (Adderall, Ritalin, Vyvanse, Concerta, etc.) require an Electronic Prescription for Controlled Substances (EPCS). Non-stimulants (Strattera, Qelbree, guanfacine ER, clonidine ER) are non-scheduled. EPCS is entirely inapplicable for these agents.
• Delaware Parity: Del. Code Ann. tit. 18, § 3343 (aligned with the federal Mental Health Parity and Addiction Equity Act). ADHD is a covered mental health condition. Cigna may not impose benefit limitations on ADHD treatment that are more restrictive than those applied to comparable medical or surgical conditions.
• Telehealth: Cigna typically covers telehealth ADHD evaluations and follow-up visits for non-controlled non-stimulant prescriptions. Stimulant prescribing via telehealth is permissible under current federal and Delaware law but requires an EPCS-compliant prescriber platform.
• Key Contacts: Cigna member services 1-800-244-6224 | ESI pharmacy 1-800-835-3784 | DE Insurance Commissioner 1-302-674-7300

Understanding Cigna’s PA Policy IP0477. The Critical 2026 Change

Effective May 15, 2026, Cigna implemented PA Policy IP0477, which extended prior authorization requirements to all stimulant medications used for ADHD. Including generics that previously required no PA. This is the most significant coverage change affecting Cigna ADHD patients in 2026 and applies to Cigna plans nationwide, including those in Delaware.

Under IP0477, the following medication categories all require PA before Cigna will cover them:

• Generic amphetamine salts (mixed amphetamine salts, dextroamphetamine)
• Generic methylphenidate (immediate-release, extended-release)
• Brand amphetamines (Adderall XR, Dexedrine)
• Brand methylphenidates (Ritalin LA, Concerta, Quillivant XR, Jornay PM)
• Lisdexamfetamine (Vyvanse)
• Methamphetamine (Desoxyn. Rarely prescribed)
• Amphetamine prodrug formulations (Mydayis)

What IP0477 does NOT require PA for:

• Atomoxetine (generic Strattera). Schedule V in some contexts but generally treated as non-stimulant non-controlled; PA may still apply for brand
• Viloxazine ER (Qelbree). Non-scheduled; PA typically required but not under IP0477 stimulant policy
• Guanfacine ER (generic Intuniv). Non-scheduled; PA may apply
• Clonidine ER (Kapvay). Non-scheduled; PA may apply

This means that even if your provider writes a prescription for a low-cost generic amphetamine or methylphenidate, ESI will require a completed PA before dispensing under your Cigna benefit. Patients who receive stimulant prescriptions without an approved PA will be responsible for the full retail cost until authorization is obtained.

ESI Formulary Overview: Cigna ADHD Medications in Delaware (2026)

Cigna uses Express Scripts (ESI) as its pharmacy benefit manager. The table below reflects the general ESI formulary structure for ADHD medications. Your specific plan’s tier and PA requirements may differ. Always verify at cigna.com or by calling ESI at 1-800-835-3784.

Tier placements and PA requirements are subject to change. Verify your specific plan’s formulary at cigna.com/drug-search or by calling ESI at 1-800-835-3784.

Delaware EPCS Requirements for ADHD Medications

Delaware requires Electronic Prescribing of Controlled Substances (EPCS) for Schedule II medications under DE Admin Code Title 24 § 1700. All stimulant ADHD medications fall under Schedule II of the federal Controlled Substances Act (21 U.S.C. § 812). This means:

Telehealth providers prescribing Schedule II stimulants in Delaware must operate on EPCS-compliant platforms. Klarity Health’s provider network uses EPCS-compliant prescribing systems where clinically appropriate and permitted under current law.

Prior Authorization Process Under IP0477: Step-by-Step

Because IP0477 applies to all stimulants. Including generics. The PA process is now a standard step for nearly all Cigna ADHD patients in Delaware. Here is how the process typically works:

1. Receive your diagnosis and prescription: Your provider evaluates your symptoms and determines a stimulant medication is clinically appropriate. They write an EPCS-compliant prescription and submit a PA request to Cigna/ESI on your behalf.
2. Cigna/ESI reviews the PA request: ESI reviews clinical criteria. Typically including confirmation of ADHD diagnosis, prior treatment history, and sometimes age-specific criteria. Standard review may take 1. 3 business days; urgent reviews 24. 72 hours.
3. Approval or denial notification: You and your provider receive written notification. If approved, your prescription is authorized for a defined fill period (often 30. 90 days, with renewal PA required).
4. If denied. Request a peer-to-peer review: Your provider can request a peer-to-peer discussion with Cigna’s medical director. This step often results in approval for clear-cut ADHD cases and should be the first step after a denial.
5. File an appeal if needed: If the peer-to-peer review does not resolve the denial, proceed to the formal appeal process outlined below.

Tip: Ask your provider’s office staff to initiate the PA at the time of your appointment. Before you attempt to fill the prescription at the pharmacy. Attempting to fill without an approved PA will result in an out-of-pocket charge at the pharmacy counter.

Delaware Mental Health Parity: Your Rights Under § 3343

Delaware’s mental health parity law, Del. Code Ann. tit. 18, § 3343, mirrors the federal Mental Health Parity and Addiction Equity Act (MHPAEA). Under § 3343, Cigna may not impose benefit limitations on ADHD treatment that are more restrictive than those applied to analogous medical or surgical conditions. This applies to:

• Prior authorization requirements (Cigna cannot require more frequent PA for ADHD medications than for comparable physical health medications)
• Step therapy / fail-first protocols (restrictions applied to ADHD drugs must be comparable to those for physical health drugs at equivalent tiers)
• Visit limits and cost-sharing for ADHD-related behavioral health visits
• Coverage of ADHD diagnosis and evaluation services

If you believe Cigna is applying more restrictive criteria to your ADHD treatment than it applies to comparable medical conditions, you may file a parity complaint with the Delaware Insurance Commissioner at 1-302-674-7300 or file a federal complaint with the U.S. Department of Labor’s Employee Benefits Security Administration (EBSA) at 1-866-444-3272 if your plan is self-funded (ERISA-governed).

Appealing a Cigna ADHD Coverage Denial in Delaware

If Cigna denies your PA for an ADHD medication, you have several avenues for appeal:

1. Internal Cigna appeal: Submit a written appeal within the timeframe specified in your denial letter (typically 180 days). Include your provider’s clinical notes, ADHD diagnosis documentation, and a letter of medical necessity.
2. Peer-to-peer review: Your prescribing provider calls Cigna’s medical director to discuss the clinical basis for the prescription. This step is free and often resolves denials for well-documented ADHD cases.
3. External review (Delaware DOI): If Cigna upholds the denial after internal appeal, you may request an independent external review through the Delaware Department of Insurance at 1-302-674-7300. Delaware law requires Cigna to comply with the external reviewer’s decision.
4. Delaware parity complaint (§ 3343): If the denial appears to reflect a more restrictive standard than applied to medical/surgical conditions, file a parity complaint with the Delaware Insurance Commissioner. Include documentation showing the disparity.
5. Federal ERISA complaint (self-funded plans): If your coverage is through an employer self-funded plan (common in large employers), file a complaint with the DOL’s EBSA at 1-866-444-3272. ERISA plans are exempt from state insurance regulation but must still comply with federal MHPAEA.

How to Verify Your Cigna ADHD Benefits Before Your Appointment

1. Call Cigna member services (1-800-244-6224): Confirm that ADHD evaluation and treatment visits are covered under your specific plan. Ask about copay/coinsurance for mental health outpatient visits.
2. Confirm telehealth coverage: Ask whether telehealth ADHD evaluations are covered at the same cost-sharing as in-person visits (parity applies to telehealth coverage under many Cigna plans).
3. Check the ESI formulary (1-800-835-3784 or esi.com): Confirm the tier placement and PA requirements for the specific ADHD medication your provider is likely to prescribe. Ask whether IP0477 applies to your plan.
4. Ask your provider about EPCS capability: If your provider plans to prescribe a Schedule II stimulant in Delaware, confirm they use an EPCS-compliant system. Klarity Health’s platform is EPCS-enabled where applicable.
5. Request pre-authorization (PA) proactively: Ask your provider to initiate the PA request at the time of your visit. Do not wait until you are at the pharmacy. IP0477 now applies to all stimulants under Cigna plans.

Check if your Cigna plan may cover ADHD treatment. Klarity Health’s 2,000+ licensed providers work with patients to navigate PA requirements, provide EPCS-compliant stimulant prescriptions where appropriate, and offer non-stimulant alternatives for patients who prefer to avoid the PA process. See if you may qualify for ADHD treatment through Klarity →

Cigna vs. Other Delaware Insurers: ADHD Coverage Comparison

Understanding how Cigna compares to other major Delaware insurers helps you make informed decisions during open enrollment or when evaluating your current plan:

• Cigna (ESI) under IP0477: ALL stimulants require PA, including generics. This is the most restrictive generic stimulant PA policy among major Delaware insurers currently.
• Highmark BCBS DE (ESI): Generic stimulants may not require PA; brand stimulants typically require PA + step therapy. Generics are more accessible than under Cigna.
• UnitedHealthcare (OptumRx): Generic stimulants often at Tier 1. 2 with no PA; brand stimulants require PA + step therapy (prior generic trial).
• Aetna (CVS/Caremark): Generic stimulants Tier 1. 2 typically no PA; brand stimulants PA + step therapy.
• Humana (HPS. Medicare Advantage only): PA required for all stimulants; Medicare ADHD treatment coverage follows CMS guidelines rather than state parity law.

Cigna’s IP0477 policy makes it important to choose a provider who initiates PA proactively and has experience navigating ESI’s review process for stimulant medications.

Frequently Asked Questions

Does Cigna cover ADHD evaluations in Delaware?

Cigna typically may cover ADHD evaluations by licensed mental health providers or physicians as outpatient mental health visits. Coverage details. Including copays and cost-sharing. Depend on your specific plan. Call Cigna at 1-800-244-6224 to verify your mental health outpatient benefits before scheduling an evaluation.

Will Cigna cover generic ADHD medications without prior authorization in 2026?

No. Under IP0477, effective May 15, 2026, all stimulant medications. Including generic amphetamine salts and methylphenidate. Require prior authorization through ESI, regardless of tier. This is a significant change from prior years when generics at Tier 1. 2 often required no PA.

Can I get my ADHD medication through telehealth with Cigna in Delaware?

Cigna typically covers telehealth visits for ADHD evaluation and non-stimulant prescribing. For Schedule II stimulants, your telehealth provider must use an EPCS-compliant prescribing platform, as required by Delaware law. Federal rules governing telehealth stimulant prescribing are subject to ongoing review; your provider will advise on current requirements at the time of your visit.

What is IP0477 and how does it affect my ADHD coverage?

IP0477 is Cigna’s prior authorization policy for stimulant medications, effective May 15, 2026. It requires PA for all stimulants. Generic and brand. Before ESI will cover them under your Cigna pharmacy benefit. Your provider must submit a PA request on your behalf and receive approval before you fill the prescription, or you will pay the full retail cost at the pharmacy.

What happens if Cigna denies my ADHD medication PA request?

You have the right to appeal. Start with your provider requesting a peer-to-peer review with Cigna’s medical director. This step often resolves denials for clearly documented ADHD. If the denial is upheld, file a formal internal appeal, and if that fails, request an external independent review through the Delaware Insurance Commissioner at 1-302-674-7300. You may also file a parity complaint under Del. Code Ann. tit. 18, § 3343 if you believe the denial reflects a standard more restrictive than applied to comparable medical conditions.

Does Delaware’s parity law (§ 3343) apply to Cigna ADHD coverage?

Yes. Del. Code Ann. tit. 18, § 3343 applies to fully insured Cigna plans in Delaware and requires that ADHD treatment benefits not be subject to more restrictive limitations than those applied to analogous medical or surgical benefits. However, if your Cigna coverage is through a large employer self-funded plan, ERISA preempts state insurance law. Your rights under MHPAEA still apply but enforcement is through the federal DOL rather than the Delaware Insurance Commissioner.

Important Contacts

• Cigna member services: 1-800-244-6224 (on back of your insurance card)
• Express Scripts (ESI) pharmacy: 1-800-835-3784
• Delaware Insurance Commissioner: 1-302-674-7300 | insurance.delaware.gov
• DOL Employee Benefits Security Administration (ERISA plans): 1-866-444-3272
• CMS (Medicare/Medicaid questions): 1-800-633-4227

Disclaimer

This page provides general educational information about how Cigna may cover ADHD treatment in Delaware in 2026. Coverage varies significantly by plan type, employer, and individual circumstances. Nothing on this page constitutes a guarantee of coverage or a statement of your specific benefits. Always verify your specific benefits by calling the member services number on the back of your Cigna insurance card before scheduling any appointment or filling any prescription. Klarity Health providers can assist with insurance-related questions but cannot guarantee coverage outcomes.